COMMUNIQUÉS West-GlobeNewswire

Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer
18/02/2026
Board-certified allergist and leading food allergy and anaphylaxis researcher joins Aquestive to support Anaphylm™ (dibutepinephrine) sublingual film NDA resubmission and pipeline WARREN, N.J., Feb. 18, 2026 (GLOBE [...]
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
18/02/2026
CAMBRIDGE, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact [...]
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis
18/02/2026
Neflamapimod endorsement based on targeted mechanism of action, demonstrated clinical activity in neurodegenerative diseases, and encouraging translational data in ALS-relevant neurotoxicity models UK-based trial first [...]
Medicenna Therapeutics Announces Participation in Upcoming Conferences
18/02/2026
TORONTO and HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]
BrainsWay Reports Cigna’s Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care
18/02/2026
BURLINGTON, Mass. and JERUSALEM, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today [...]
Medline announces participation in the Barclays 28th Annual Global Healthcare Conference
18/02/2026
NORTHFIELD, Ill., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that Jim Boyle, Chief Executive Officer, and Mike Drazin, Chief Financial Officer, are scheduled to present at [...]
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
18/02/2026
ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and gynecological cancers in first-line and previously treated patients Company [...]
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
18/02/2026
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 18 February 2026) Immunocore Holdings [...]
Helsinn announces European Commission approval of AKYNZEO® Oral Suspension
18/02/2026
Lugano, Switzerland – February 18th, 2026 – Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, today announced that the European Commission [...]
NewBiologix Announces Publication of Breakthrough HEK293 Cell Line Optimized for High-Quality rAAV Production
18/02/2026
Paper reports two-fold higher full-to-empty rAAV ratio using NBX1P01 compared to a leading commercial HEK293 cell line LAUSANNE, Switzerland, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NewBiologix S.A., a biotechnology company [...]
Bavarian Nordic Receives USD 22.5 Million Contract for its Mpox and Smallpox Vaccine from the Government of Canada
18/02/2026
COPENHAGEN, Denmark, February 18, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced a new order valued at USD 22.5 million from the Public Health Agency of Canada (PHAC) for the Company’s mpox and smallpox vaccine [...]
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
18/02/2026
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types 1 Remibrutinib, a highly selective oral BTK inhibitor, was well-tolerated and [...]
Defeating the "Cold Chain" Barrier: Bio Usawa and Nanoly Bioscience Announce Strategic $500 Million Licensing Agreement for Breakthrough DynaShield™ Technology
18/02/2026
SAN FRANCISCO and LOS ANGELES and KIGALI, Rwanda, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bio Usawa, a leader in expanding global access to biopharmaceuticals, and Nanoly Bioscience, a pioneer in chemical stabilization, today [...]
Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830
18/02/2026
Press release – No. 4 / 2026 Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830 Single doses of ZP9830 were well tolerated, with no serious or severe adverse events or dose- [...]
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
18/02/2026
MIRAMAR, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
17/02/2026
CONSHOHOCKEN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
BrightSpring Health Services, Inc. to Host Investor Day on March 17, 2026
17/02/2026
LOUISVILLE, Ky., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it will host an Investor Day on Tuesday, March 17, 2026 [...]
Voting Rights and Shares Capital of the Company
17/02/2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Feb. 17, 2026 (GLOBE NEWSWIRE [...]
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
17/02/2026
–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital– REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, [...]

Pages